LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Kodu・Aktsiate loetelu・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Suletud

SektorTervishoid

3.48 -3.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.45

Max

3.61

Põhinäitajad
By Trading Economics
Sissetulek	8.3M -18M
Müük	9.6M 10M
P/E Sektori keskmine	22.5 51.415
Aktsiakasum	-0.1
Kasumimarginaal	-177.89
Töötajad	69
EBITDA	8M -19M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+260.11% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-70M 840M
Eelmine avamishind	6.81
Eelmine sulgemishind	3.48

Uudiste sentiment

By Acuity

34%

66%

69 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

0.7658 / N/A Toetus ja vastupanu

CytomX Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. mai 2026, 23:53 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15. mai 2026, 22:47 UTC

Kuumad aktsiad

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. mai 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. mai 2026, 22:00 UTC

Suurimad hinnamuutused turgudel

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. mai 2026, 18:09 UTC

Suurimad hinnamuutused turgudel

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17. mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17. mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17. mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17. mai 2026, 23:07 UTC

Omandamised, ülevõtmised, äriostud

UOB: Transactions Part of Group's Capital Reallocation Strategy

17. mai 2026, 23:06 UTC

Omandamised, ülevõtmised, äriostud

UOB: Share Sale Agreements Entered With Singland Properties

17. mai 2026, 23:05 UTC

Omandamised, ülevõtmised, äriostud

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Fund Stake Acquisition via Internal Resources

17. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Acquire Stake for $389 Million

17. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16. mai 2026, 16:27 UTC

Omandamised, ülevõtmised, äriostud

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16. mai 2026, 15:26 UTC

Omandamised, ülevõtmised, äriostud

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16. mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. mai 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 20:19 UTC

Kuumad aktsiad

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. mai 2026, 19:41 UTC

Omandamised, ülevõtmised, äriostud

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. mai 2026, 18:35 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

CytomX Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

260.11% tõus

12 kuu keskmine prognoos

Keskmine 13 USD 260.11%

Kõrge 16 USD

Madal 11 USD

Põhineb 9 Wall Streeti analüütiku instrumendi CytomX Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi CytomX Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.7658 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

69 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.